Athanor Capital, LP Merus N.V. Transaction History

Athanor Capital, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$20.0 - $25.48 $680,420 - $866,855	-34,021 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$16.14 - $29.11 $224,136 - $404,250	-13,887 Reduced 28.99%	34,021 $711,000
Q4 2020 Feb 16, 2021	BUY	$11.4 - $18.36 $34,200 - $55,080	3,000 Added 6.68%	47,908 $840,000
Q3 2020 Nov 16, 2020	SELL	$10.57 - $16.0 $21,879 - $33,120	-2,070 Reduced 4.41%	44,908 $539,000
Q2 2020 Aug 13, 2020	BUY	$10.5 - $17.36 $64,638 - $106,868	6,156 Added 15.08%	46,978 $756,000
Q1 2020 May 14, 2020	SELL	$11.34 - $19.44 $35,029 - $60,050	-3,089 Reduced 7.03%	40,822 $494,000
Q4 2019 Feb 14, 2020	SELL	$14.08 - $18.5 $212,241 - $278,869	-15,074 Reduced 25.56%	43,911 $618,000
Q3 2019 Nov 14, 2019	BUY	$14.55 - $20.52 $526,710 - $742,824	36,200 Added 158.88%	58,985 $1.05 Million
Q2 2019 Aug 13, 2019	BUY	$12.93 - $16.83 $294,610 - $383,471	22,785 New	22,785 $334,000

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.